Introduction {#Sec1}
============

Congenital hearing loss is one of the most common sensory disorders, affecting one out of 500--1000 newborns. Over half of the cases of congenital or early onset sensorineural hearing loss are estimated to be caused by genetic factors^[@CR1]^, with 30% of these hereditary hearing loss patients affected by various syndromes. More than 400 syndromes associated with hearing loss and other symptoms have been described^[@CR2]^.

The most commonly observed syndromes in clinical settings include Pendred syndrome, BOR syndrome, Waardenburg syndrome, osteogenesis imperfecta, Stickler syndrome, spondyloepiphyseal dysplasia congenita, CHARGE syndrome, Klippel-Feil syndrome, Alport syndrome, Treacher-Collins syndrome, Jervell Lange-Nielsen syndrome, Perrault syndrome, Norrie disease, and auditory neuropathy with optic atrophy. The clinical characteristics and responsible genes for these 14 syndromes are summarized in Table [1](#Tab1){ref-type="table"}.Table 1The clinical characteristics and responsible genes for 14 types of syndromic hearing loss.SyndromeOMIM\#PrevalenceGene and inheritanceClinical featuresReferenceBranchio-oto-renal (BOR) syndrome113650, 602588, 608389, 6108961:40,000*EYA1* (AD), *SIX1* (AD), *SIX5* (AD)hearing loss, branchial anomalies, preauricular pits, renal anomalies, anomalies of the external, middle, inner ear, and others^[@CR3],\ [@CR4]^Waardenburg syndrome (WS) type 11935001:20,000--40,000 for all types of WS*PAX3* (AD)hearing loss, pigmentation disturbances of the hair, skin and eyes, dystopia canthorum^[@CR5]--\ [@CR9]^Waardenburg syndrome (WS) type 2193510, 608890, 611584*MITF* (AD), *SNAI2* (AR), *SOX10* (AD), *EDNRB* (AD),hearing loss, pigmentation disturbances of the hair, skin and eyes^[@CR5]--\ [@CR9]^Waardenburg syndrome (WS) type 3148820*PAX3* (AD)hearing loss, pigmentation disturbances of the hair, skin and eyes, dystopia canthorum, upper limb abnormalities^[@CR5]--\ [@CR9]^Waardenburg syndrome (WS) type 4277580, 613265, 613266*EDNRB* (AD/AR), *EDN3* (AD/AR), *SOX10* (AD),hearing loss, pigmentation disturbances of the hair, skin and eyes, Hirschsprung disease^[@CR5]--\ [@CR9]^Osteogenesis imperfecta166200, 166210, 259420, 1662201:15,000--20,000*COL1A1* (AD), *COL1A2* (AD)hearing loss, multiple bone fractures, blue sclera, otosclerosis^[@CR10]^Spondyloepiphyseal displasia congenita183900unknown*COL2A1* (AD)hearing loss, short stature, abnormal epiphyses, flattened body^[@CR11]^Stickler syndrome108300, 604841, 614134, 6142841:7,500--9,000*COL2A1* (*AD*), *COL11A1* (AD), *COL9A1* (AR), *COL9A2* (AR), *COL9A3* (AR)hearing loss, cleft palate, midfacial hypoplasia, arthritis, eye sympton (myopia, retinal retachment)^[@CR12]--\ [@CR16]^Stickler syndrome (non-ocular type)unknown*COL11A2* (AD/AR)hearing loss, cleft palate, midfacial hypoplasia, arthritis^[@CR12],\ [@CR17]^Alport syndrome301050, 203780, 1042001:50,000*COL4A5* (XLD), *COL4A3* (AD/AR), *COL4A4* (AR)hearing loss, eye sympton, renal dysfunction^[@CR18]--\ [@CR20]^CHARGE syndrome2148001:8,500--10,000*CHD7* (AD), *SEMA3E* (AD)hearing loss/ear anomalies, coloboma, heart defect, choanal atresia, retarded growth and development, genital hypoplasia^[@CR21]--\ [@CR24]^Jervell and Lange-Nielsen syndrome220400, 6123471:200,000*KCNQ1* (AR), *KCNE1* (AR)hearing loss, a long QT interval with torsade de pointes on an electrocardiogram^[@CR25],\ [@CR26]^Pendred syndrome2746001:10,000--13,000*SLC26A4* (AR)hearing loss, goiter, enlarged vestibular aqueduct^[@CR27]^Klippel-Feil syndrome118100, 2143001:40,000--42,000*GDF6* (AD), *MEOX1* (AR), *GDF3* (AD), *MYO18B* (AR)hearing loss, short neck (fusion of cevicalvertebrae), low posterior hairline^[@CR59]^Auditory neuropathy with optic atrophyunknown*OPA1* (AD)hearing loss, visual impairment (optic atrophy)^[@CR60]^Treacher-Collins syndrome154500, 2483901:50,000*TCOF1* (AD), *POLR1D* (AD/AR), *POLR1C* (AR)hearing loss malformations of ear, eye, and mandibulaNorrie disease310600unknown*NDP* (AR)hearing loss, eye symptoms (pseudoglioma, blindness), mental retardationPerrault syndrome233400, 614926, 614129, 615300unknown*HSD17B4* (AR), *HARS2* (AR), *CLPP* (AR), *LARS2* (AR), *TWNK* (AR), *ERAL1* (AR)hearing loss, ovarian dysgenesis (in females)AD: Autosomal dominant, AR: Autosomal recessive, XLD: X-linked dominant. Responsible genes, prevalence, inheritance and clinical feature informations were obtained from OMIM database (<https://www.omim.org>), GeneReviews^®^, StatPearls and each reference.

Branchio-Oto-Renal (BOR) syndrome (OMIM\#113650 and \#610896) or Branchio-Oto (BO) syndrome (OMIM\#602588 and 608389) is characterized by the association of the branchial arch, external ear anomalies, hearing impairment and renal anomalies. BO/BOR syndrome is observed in one out of 40,000 children, and in 2% of profoundly deaf children^[@CR3],[@CR4]^.

Waardenburg syndrome (WS1 OMIM\#193500, WS2 OMIM\#193510, \#608890 and \#611584, WS3 OMIM\#148820, WS4 OMIM\#277580, \#613265 and \#613266) is characterized by varying degrees of hearing impairment and pigmentation disturbances in the hair, skin and eyes^[@CR5],[@CR6]^. WS is classified into four types based on clinical findings. The frequency of WS is 1/20,000--40,000 newborns^[@CR5]--[@CR9]^. Osteogenesis imperfecta type 1 (OMIM\#166200) is an autosomal dominant inheritance disorder characterized by fractures with minimal or no trauma, blue sclera, hearing loss and otosclerosis^[@CR10]^.

Spondyloepiphyseal dysplasia congenita (OMIM\#183900) is an autosomal dominantly inherited chondrodysplasia characterized by a disproportionately short stature (short trunk), abnormal epiphyses and flattened vertebral bodies^[@CR11]^.

Stickler syndrome (OMIM\#108300, \#604841, \#614134 and \#614284) is an inherited connective tissue disorder associated with myopia, retinal detachment, cleft palate, midfacial hypoplasia, arthritis and hearing impairment^[@CR12]--[@CR17]^. Alport syndrome (OMIM\#301050, \#203780 and \#104200) is a progressive disease associated with glomerulonephritis, sensorineural hearing loss, and ocular complications caused by abnormalities in type IV collagen^[@CR18]--[@CR20]^.

CHARGE syndrome (OMIM\#214800) is an autosomal dominant disorder characterized by congenital multiple anomalies ([c]{.ul}oloboma, [h]{.ul}eart defect, choanal [a]{.ul}tresia, [r]{.ul}etarded growth and development, [g]{.ul}enital hypoplasia and [e]{.ul}ar anomalies/deafness)^[@CR21]--[@CR24]^.

Jervell and Lange-Nielsen syndrome (OMIM\#220400 and \#612347) is a rare autosomal recessive cardio-auditory disorder characterized by congenital profound bilateral sensorineural hearing loss and a long QT interval with arrhythmia (torsade de pointes)^[@CR25],[@CR26]^

Pendred syndrome (OMIM\#274600) is an autosomal recessive disorder characterized by congenital hearing loss, goiter, and enlarged vestibular aqueduct^[@CR27]^.

In this study, we conducted a comprehensive analysis of 140 Japanese syndromic hearing loss patients to obtain the mutation spectrums and clinical features by using next-generation sequencing (NGS) analysis with a multiple syndromic targeted resequencing panel.

Results {#Sec2}
=======

As shown in Table [2](#Tab2){ref-type="table"}, we performed NGS analysis of 36 previously reported genes associated with syndromic hearing loss for 140 probands and identified the causative gene variants in 79 probands (56%). The diagnostic rate by syndrome was 32% (19/59) for BOR syndrome, 78% (18/23) for Waardenburg syndrome, 60% (3/5) for osteogenesis imperfecta, 100% (3/3) for Stickler syndrome, and 89% (32/36) for Pendred syndrome. On the other hand, we could not detect any causative gene variants for Klippel-Feil syndrome, Alport syndrome or Norrie disease cases.Table 2Subjects and diagnostic ratio in this study.Clinical diagnosisProbandsGenetic diagnosisDiagnostic rateBranchio-oto-renal syndrome59*EYA1*: 18 cases, *SIX1*: 1 case32%Waardenburg syndrome 15*PAX3*: 2 cases, *MITF*: 1 case, *SOX10*: 1 case80%Waardenburg syndrome 214*MITF*: 4 cases, *SOX10*: 5 cases, *EDNRB*: 1 case71%Waardenburg syndrome (unclassifiable WS1 or WS2)2*PAX3*: 2 cases100%Waardenburg syndrome 42*SOX10*: 2 cases100%Osteogenesis imperfecta5*COL1A1*: 3 cases60%Stickler syndrome3*COL11A1*: 2 cases, *COL11A2*: 1 case100%Spondyloepiphyseal dysplasia congenita1*COL2A1*: 1 case100%CHARGE syndrome3*CHD7*: 1 case33%Jervell and Lange-Nielsen syndrome1*KCNQ1*(compound heterozygous): 1 case100%Pendred syndrome36*SLC26A4*(compound heterozygous or homozygous): 32 cases89%Klippel-Feil syndrome30%Alport syndrome40%Treacher-Collins syndrome0NANorrie disease10%Perrault syndrome0NAAuditory neuropathy with optic atrophy1*OPA1*: 1 case100%Total1407956%

Mutation spectrum and clinical features of BOR syndrome patients {#Sec3}
----------------------------------------------------------------

We conducted genetic analysis of 59 probands with clinical findings of BO/BOR syndrome (16 typical cases, 43 atypical cases, Supplementary Table [S1](#MOESM1){ref-type="media"}), and identified causative heterozygous variants in 19 probands (diagnostic rate 32%). We identified the causative variants in 12/16 typical cases, but the causative variants were identified in only 7/43 atypical cases. Table [3](#Tab3){ref-type="table"} summarizes the identified variants and clinical features of the probands and all affected family members for 18 families with *EYA1* mutations, and one family with a *SIX1* mutation. There were no BO/BOR cases caused by the *SIX5* gene variant. Among the 12 *EYA1* variants, 8 were truncating variants (five were nonsense, one was frameshift, two were splice site), three were missense variants and one was a copy number variation (one copy number loss). Four of them were novel variants and 8 of them were previously reported. JHLB4043 had one copy loss detected using NGS read depth data, which seemed to be deleted in all of the *EYA1* gene, confirmed by array Comparative Genomic Hybridization (aCGH). The mutations identified in this study were located in exon 6 to exon 13, and frequently observed in exon 8 and exon 12. Two or more cases carried the same variants (p.R264X, p.R275X, c.867 + 5 G \> A, p.R328X and p.R407Q). *EYA1* variants were mainly identified from autosomal dominant families (10/18 cases); however, we also identified variants from 7 sporadic cases. Among them we confirmed *de novo* mutations in four families (Supplementary Fig. [S1](#MOESM1){ref-type="media"}). The case with a *SIX1* mutation was also caused by *de novo* mutation (Supplementary Fig. [S1](#MOESM1){ref-type="media"}). In terms of the clinical features of all BO/BOR-affected patients with *EYA1* and *SIX1* gene variants (19 probands and their family members who carried the same variants; 34 patients in total), the most frequent symptom was hearing loss (31/ 32, 97%). Unilateral hearing loss was observed in 2 cases. The most frequent type of hearing loss was moderate mixed hearing loss. Middle and/or inner ear anomalies were observed in 22 of 23 cases who underwent CT imaging (96%). Twenty-seven of 31 cases had preauricular pits (87%), and 14 of 25 cases for whom information was available had branchial anomalies (56%). Renal anomalies, on the other hand, were revealed in only one of 7 cases for whom kidney abnormalities were examined (14%). It is noteworthy that there were only a limited number of cases (7/34) with renal ultrasonographic information available in our cohort, thus the frequencies of renal anomalies may be underestimated. The presence of branchial or renal anomalies was not correlated with the severity of hearing loss. Furthermore, no relationship was found between genotype and clinical findings. As rare symptoms, one patient had hemifacial palsy, and 3 cases had eye symptoms.Table 3Genetic diagnosis results and clinical features of BO/BOR syndrome patients and family members.ProbandFamilyTypeNucleotide changeAmino Acid changeLocationHereditary formSeverity of hearing lossPreauricular pitsCervical fistulaEar marformationRenal anomalyOther clinical featuresreferenceRt.earLt.earInner earMiddle earExternal earJHLB-6679probandtypical*EYA1*: c. \[489T \> G\]; \[=\]p.\[Y163X\];\[=\]exon 6ADmoderatemoderate+−+++−−this studyfatheratypical*EYA1*: c. \[489T \> G\]; \[=\]p.\[Y163X\];\[=\]exon 6moderatemoderate+−NANANA−−brotherNA*EYA1*: c. \[489T \> G\]; \[=\]p.\[Y163X\];\[=\]exon 6NANANANANANANANANAmotherunaffected*EYA1*: c. \[=\]; \[=\]normalnormal−−NANANANANAJHLB346probandtypical*EYA1*: c. \[790C \> T\]; \[=\]p.\[R264X\];\[=\]exon 8ADmildnormal++NANANANANARickard (2000), Fukuda (2001)JHLB3868probandatypical*EYA1*: c. \[790C \> T\]; \[=\]p.\[R264X\];\[=\]exon 8ADmoderate(COR)+−+NANANA−Rickard (2000), Fukuda (2001)grandfathertypical*EYA1*: c. \[790C \> T\]; \[=\]p.\[R264X\];\[=\]exon 8moderateprofound++NANANANA−mothertypical*EYA1*: c. \[790C \> T\]; \[=\]p.\[R264X\];\[=\]exon 8moderatemoderate++NANANANA−fatherunaffected*EYA1*: c. \[=\]; \[=\]NANA−−NANANANANAgrandmotherunaffected*EYA1*: c. \[=\]; \[=\]NANA−−NANANANANA\#4107probandtypical*EYA1*: c.\[823C \> T\]; \[=\]p.\[R275X\];\[=\]exon 8ADmoderatemild+NA++NANA−Abdelhak (1997), Orten (2008)motheratypical*EYA1*: c.\[823C \> T\]; \[=\]p.\[R275X\];\[=\]exon 8profoundmoderateNA+NA+NANA−JHLB2279probandtypical*EYA1*: c. \[823C \> T\]; \[=\]p.\[R275X\];\[=\]exon 8sporadic (*de novo*)moderatemoderate++++NA−−Abdelhak (1997), Orten (2008)fatherunaffected*EYA1*: c. \[=\]; \[=\]NANA−−NANANANANAmotherunaffected*EYA1*: c. \[=\]; \[=\]NANA−−NANANANANA\#371probandatypical*EYA1*: c.\[867 + 5G \> A\];\[=\]intron 8sporadicmildprofound+−NANANANA−Stockley (2008)JHLB4689probandtypical*EYA1*: c.\[867+5G \> A\]; \[=\]intron 8ADmoderatemoderate++NA+NANA−Stockley (2008)brotheratypical*EYA1*: c.\[867+5G \> A\]; \[=\]intron 8moderatemoderate+NANA+NANA−motheratypical*EYA1*: c.\[867+5G \> A\]; \[=\]intron 8mildmild+NANANANANANAgrandmotheratypical*EYA1*: c.\[867+5 G \> A\]; \[=\]intron 8profoundsevere−−NANANANANAJHLB2062probandatypical*EYA1*: c. \[982 C \> T\]; \[=\]p.\[R328X\];\[=\]exon 10sporadic (*de novo*)profoundprofound+NA+NANA−vision Zimpair-mentSpruijt (2006), Olavarrieta (2008)fatherunaffected*EYA1*: c. \[=\]; \[=\]NANANANANANANANANAmotherunaffected*EYA1*: c. \[=\]; \[=\]NANANANANANANANANAJHLB2922probandtypical*EYA1*: c. \[982 C \> T\]; \[=\]p.\[R328X\];\[=\]exon 10sporadicmoderatemoderate++++NANA−Spruijt (2006), Olavarrieta (2008)JHLB3360probandtypical*EYA1*: c. \[982C \> T\]; \[=\]p.\[R328X\];\[=\]exon 10ADnormalnormal++−NANA+−Spruijt (2006), Olavarrieta (2008)motheratypical*EYA1*: c. \[982C \> T\]; \[=\]p.\[R328X\];\[=\]exon 10profoundprofound+NANANANA−−JHLB975probandatypical*EYA1*: c. \[1090C \> T\]; \[=\]p.\[Q364X\];\[=\]exon 11NANANA+NA+NANANANAthis studyJHLB3266probandatypical*EYA1*: c. \[1101-1G \> A\]; \[=\]intron 11ADseveresevere−++NANANAamblyopia. hyperopiaRetterer (2016)motheratypical*EYA1*: c. \[1101-1G \> A\]; \[=\]intron 11severeprofound−−NANANANAhyperopiauncleatypical*EYA1*: c. \[1101-1G \> A\]; \[=\]intron 11severeprofound−−+NANANANAJHLB2645probandtypical*EYA1*: c. \[1155_1156delAT\]; \[=\]p. \[L385fs\];\[=\]exon 12sporadic (*de novo*)severemoderate++++NANA−this studyfatherunaffected*EYA1*: c. \[=\]; \[=\]NANANANANANANANANAmotherunaffected*EYA1*: c. \[=\]; \[=\]NANANANANANANANANAsisterunaffected*EYA1*: c. \[=\]; \[=\]NANANANANANANANANA\#4361probandtypical*EYA1*: c. \[1187A \> G\]; \[=\]p.\[D396G\];\[=\]exon 12ADprofoundsevere+++NANANA−Namba (2001)daughteratypical*EYA1*: c. \[1187A \> G\]; \[=\]p.\[D396G\];\[=\]exon 12normalprofound+NANANANANANA\#4079probandatypical*EYA1*: c.\[1220G \> A\]; \[=\]p.\[R407Q\];\[=\]exon 12sporadic (*de novo*)mildmoderate+−+NANANA−Chang (2004)fatherunaffected*EYA1*: c. \[=\]; \[=\]NANANANANANANANANAmotherunaffected*EYA1*: c. \[=\]; \[=\]NANANANANANANANANAJHLB2233probandtypical*EYA1*: c. \[1220G \> A\]; \[=\]p.\[R407Q\];\[=\]exon 12ADsevere(COR)+−++−NA−Chang (2004)mothertypical*EYA1*: c. \[1220G \> A\]; \[=\]p.\[R407Q\];\[=\]exon 12profoundmoderate+++++−facial palsyJHLB2717probandatypical*EYA1*: c. \[1376G \> C\]; \[=\]p.\[R459P\];\[=\]exon 13sporadicseveresevereNA++NANANA−Orten (2008)JHLB4043probandtypical*EYA1*: c.(?\_72111486_72268810\_?)CNVADprofoundprofound+−+++NA− this studybrothertypical*EYA1*: c.(?\_72111486_72268810\_?)CNVmoderatemoderate++++−NA−fathertypical*EYA1*: c.(?\_72111486_72268810\_?)CNVprofoundsevere+−++−NA−JHLB660probandtypical*SIX1*: c.\[519G \> C\]; \[=\]p. \[K173N\];\[=\]exon 1sporadic (*de novo*)profound(COR)+NA++−NA−Unzaki (2018)fatherunaffected*SIX1*: c.\[=\]; \[=\]NANANANANANANANANAmotherunaffected*SIX1*: c.\[=\]; \[=\]NANANANANANANANANAAD: Autosomal dominant, COR: Conditioned orientation response audiometry.The reference cDNA sequences NM_172060 for *EYA1* and NM_005982 for *SIX1*.

Mutation spectrum and clinical features of Waardenburg syndrome patients {#Sec4}
------------------------------------------------------------------------

We conducted genetic analysis of 23 probands with hearing loss and one or more clinical findings typical of Waardenburg syndrome, and identified the causative heterozygous variants in 18 probands (diagnostic rate 78%). Table [4](#Tab4){ref-type="table"} and Supplementary Fig. [S2](#MOESM1){ref-type="media"} provides a summary of the identified variants and clinical features of probands and all family members (four families with *PAX3* mutations, five families with *MITF* mutations, 8 families with *SOX10* mutations, and one family with a *EDNRB* mutation). No pathogenic variants were found in *SNAI2* or *EDN3*. Most of the identified variants were truncating variants (four were nonsense, 7 were frameshift, one was splice site) and only three cases had missense variants, one each in *PAX3*, *MITF* and *SOX10*. In addition, we also identified three cases with one copy number loss of the *SOX10* gene identified from NGS read depth data and confirmed by aCGH. Thirteen variants were novel and five variants (three *PAX3* mutations, and one each with *MITF* and *SOX10* mutations) were previously reported. Computer prediction scores, allele frequency information and the pathogenicity classification for novel variants are listed in Supplementary Table [S2](#MOESM1){ref-type="media"}. Autosomal dominant inherited cases were 2/4 in *PAX3* cases, 4/5 in *MITF* cases, 1/8 in *SOX10* cases, and 1/1 in *EDNRB* cases. The other 10 cases were sporadic cases, with confirmed *de novo* mutations in *SOX10* in five cases (Table [4](#Tab4){ref-type="table"}). In terms of the clinical features of the probands and all family members harboring the same causative gene variants (29 patients from 18 families in total), the most frequent symptom was hearing loss (27/29, 93%), followed by heterochromia iridis (23/28, 82%). The severity of hearing loss for each gene is shown in Fig. [1](#Fig1){ref-type="fig"}, with the frequency of the profound hearing loss higher in cases with *MITF* and *SOX10* mutations. Two cases with *PAX3* mutations had bilateral normal hearing and three cases with *MITF* mutations had unilateral hearing loss. Only a limited number of patients showed discoloration of the hair and skin: hair discoloration was seen in two cases (with *SOX10* and *MITF* mutations), leukoderma in one case with a *SOX10* mutation, and excessive freckles in three cases with *MITF* mutations. No abnormal musculoskeletal findings were observed in any case. Dystopia canthorum was seen in two cases with *PAX3* mutations, and one each with *MITF* and *SOX10* mutations. The other associated symptoms observed in *SOX10* cases were ptosis (JHLB4270, JHLB4310), developmental delay (JHLB4310) and Asperger syndrome (JHLB3480). In addition, inner ear anomalies, including hypoplasia of the semicircular canal, cochlea, cochlear nerve, and saccular vestibule, were observed. It is suggested that there is no obvious correlation between the type of mutation and its location and the severity of the symptoms. Most of the clinical findings for cases associated with each gene were in agreement with previous reports; however, we identified phenotype-genotype disagreement in two Waardenburg syndrome 1 (WS1) cases (JHLB2469 with a *MITF* mutation and JHLB5132 with a *SOX10* mutation).Table 4Genetic diagnosis results and clinical features of Waardenburg syndrome patients and family members.Clinical diagnostic typeProbandFamilyNucleotidechangeAmino Acid changeLocationHereditary formSeverity of hearing lossDystopia canthorumHeterochromiaOther clinical featuresReferenceRt.earLt.earWS1JHLB1588proband*PAX3*: c.\[667C \> T\];\[=\]p.\[R223X\];\[=\]exon 5sporadicmoderate(COR)++−Baldwin (1994)JHLB1655proband*PAX3*:c. \[792+1G \> A\];\[=\]intron 5ADprofound(COR)++−Wollnik (2003)father (U)*PAX3*:c. \[792+1G \> A\];\[=\]intron 5normalnormal−−−JHLB2469proband*MITF*: c.\[332C \> T\];\[=\]p.\[A111V\];\[=\]exon 3sporadicnormalsevere++−Chen (2010)JHLB5132proband*SOX10*: c.(38369847_38379751\_?)delCNVADprofoundprofound++−this studygrandfather*SOX10*: c.(38369847_38379751\_?)delCNVNANANA+−mother*SOX10*: c.(38369847_38379751\_?)delCNVNANANANAfather (U)*SOX10*: c.\[=\];\[=\]NANANA−NAbrother (U)*SOX10*: c.\[=\];\[=\]normalnormalNA−NAgrandmother (U)*SOX10*: c.\[=\];\[=\]NANANA−NAWS2JHLB2091proband*MITF*: c.\[326dupC\];\[=\]p.\[S109fs\];\[=\]exon 3ADprofound(COR)−+−this studybrother*MITF*: c.\[326dupC\];\[=\]p.\[S109fs\];\[=\]exon 3profound(COR)−+−mother*MITF*: c.\[326dupC\];\[=\]p.\[S109fs\];\[=\]exon 3profoundprofound−−HD, FRfather (U)*MITF*: c.\[=\];\[=\]p.\[=\];\[=\]profoundprofound−−NAJHLB1623proband*MITF*: c.\[389_399del\];\[=\]p.\[Y130fs\];\[=\]exon 4ADprofoundprofound−+FRthis studyfather*MITF*: c.\[389_399del\];\[=\]p.\[Y130fs\];\[=\]exon 4profoundnormal−−FRbrother*MITF*: c.\[389_399del\];\[=\]p.\[Y130fs\];\[=\]exon 4severesevere−−−mother (U)*MITF*: c.\[=\];\[=\]p.\[=\];\[=\]normalnormal−−−JHLB1593proband*MITF*: c.\[550G \> T\];\[=\]p.\[E184X\];\[=\]exon 5ADseveresevere−+−this studymother*MITF*: c.\[550G \> T\];\[=\]p.\[E184X\];\[=\]exon 5profoundprofound−+−JHLB3463proband*MITF*: c.\[796G \> T\];\[=\]p.\[E266X\];\[=\]exon 8ADprofoundprofound−+−this studymother*MITF*: c.\[796G \> T\];\[=\]p.\[E266X\];\[=\]exon 8normalprofound−+−JHLB175proband*SOX10*: c.\[400_417del\];\[=\]p.\[L134fs\];\[=\]exon 2sporadic (*de novo*)profoundprofound−+HD, MAthis studyfather (U)*SOX10*: c.\[=\];\[=\]p.\[=\];\[=\]normalnormal−−NAmother (U)*SOX10*: c.\[=\];\[=\]p.\[=\];\[=\]normalnormal−−NAJHLB1632proband*SOX10*: c.\[426G \> C\];\[=\]p.\[W142C\];\[=\]exon 2sporadicprofoundprofound−+−this studymother (U)*SOX10*: c.\[=\];\[=\]p.\[=\];\[=\]NANA−−NAJHLB4310proband*SOX10*: c.\[1195C \> T\];\[=\]p.\[Q399X\];\[=\]exon 4sporadic (*de novo*)profoundprofound−−MA, PT, MRzazo seco (2017)father (U)*SOX10*: c.\[=\];\[=\]p.\[=\];\[=\]NANANANANAmother (U)*SOX10*: c.\[=\];\[=\]p.\[=\];\[=\]NANANANANAJHLB177proband*SOX10*: c.(?\_38369393_38379751\_?)delCNVsporadic (*de novo*)profoundprofound−+MAthis studyfather (U)*SOX10*: c.\[=\];\[=\]NANA−−−mother (U)*SOX10*: c.\[=\];\[=\]NANA−−−JHLB3086proband*SOX10*: c.(?\_38369393_38379751\_?)delCNVsporadic (*de novo*)moderate(COR)−+SD, MAthis studyfather (U)*SOX10*: c.\[=\];\[=\]NANA−−NAmother (U)*SOX10*: c.\[=\];\[=\]NANA−−NAJHLB2550proband*EDNRB*: c.\[223delG\];\[=\]p.\[D75fs\];\[=\]ADmoderatesevere−+−this studymother*EDNRB*: c.\[223delG\];\[=\]p.\[D75fs\];\[=\]unilateralNA−+−Unclassifiable (WS1 or WS2)JHLB3591proband*PAX3*: c.\[318delC\];\[=\]p.\[P106fs\];\[=\]exon 2sporadicprofoundprofoundNA+−this studyJHLB2343proband*PAX3*: c.\[812G \> A\];\[=\]p.\[R271H\];\[=\]exon 6ADsevere(COR)NA+−Tassabehji (1995)father*PAX3*: c.\[812G \> A\];\[=\]p.\[R271H\];\[=\]exon 6normalnormalNA+−mother (U)*PAX3*: c.\[=\];\[=\]p.\[=\];\[=\]NANA−−NAWS4JHLB4270proband*SOX1*0: c.\[781_793del\];\[=\]p.\[R261fs\];\[=\]exon 4sporadicseveresevere−+HI, PTthis studyJHLB3480proband*SOX10*: c.\[859delT\];\[=\]p.\[S287fs\];\[=\]exon 4sporadic (*de novo*)severesevere−+HI, MA, ASthis studyfather (U)*SOX10*: c.\[=\];\[=\]p.\[=\];\[=\]normalnormal−−NAmother (U)*SOX10*: c.\[=\];\[=\]p.\[=\];\[=\]normalnormal−−NAsister (U)*SOX10*: c.\[=\];\[=\]p.\[=\];\[=\]normalnormal−−NAsister (U)*SOX10*: c.\[=\];\[=\]p.\[=\];\[=\]normalnormal−−NAU: Unaffected family member, AD: Autosomal dominant, CNV: Copy number variation, COR: Conditioned orientation audiometory.HD: Hair discoloration, SD: Skin discoloration, FR: Freckles, HI: Hirschsprung disease, MA: Malformation of inner ear, PT: Ptosis, MR: Mental retardation, AS: Asperger syndrome.The reference cDNA sequences NM_181457 for *PAX3*, NM_000248 for *MITF*, NM_006941 for *SOX10*, NM_000115 for *EDNRB*.Figure 1The degree of hearing loss for all family members harboring causative variants. We calculated the hearing threshold in the worse hearing ear. Unilateral hearing loss: *MITF* 3 cases, *EDNRB* 1 case.

Mutation spectrum and clinical features of other syndromic hearing loss patients {#Sec5}
--------------------------------------------------------------------------------

We also conducted genetic analysis of other syndromic hearing loss patients (five osteogenesis imperfecta cases, one spondyloepiphyseal dysplasia congenita case, three Stickler syndrome cases, three CHARGE syndrome cases, one Jervell and Lange-Nielsen syndrome case, one auditory neuropathy with optic atrophy case, and 36 Pendred syndrome cases). The diagnostic rate for each syndrome was 60% for osteogenesis imperfecta with *COL1A1* variants (3/5), 100% for spondyloepiphyseal dysplasia congenita with a *COL2A1* variant (1/1), 100% for Stickler syndrome with *COL11A1*, *COL11A2* variants (2/3, 1/3), 33% for CHARGE syndrome with a *CHD7* variant (1/3), 100% for Jervell and Lange-Nielsen syndrome with a *KCNQ1* variant (1/1), 100% for auditory neuropathy with a *OPA1* mutation (1/1), and 89% for Pendred syndrome with *SLC26A4* variants (32/36). Tables [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} provide summaries of the identified variants and clinical features of the probands and all family members harboring the same variants (the pedigrees and audiograms of these cases are shown in Supplementary Figs [S3](#MOESM1){ref-type="media"}, [S4](#MOESM1){ref-type="media"}). The identified variants in all three probands with osteogenesis imperfecta were previously reported truncating variants. All four affected cases had easily fractured bones, blue sclera and hearing loss. The severity of hearing loss varied from mild to severe with air-bone gap. All three probands were from autosomal dominant families.Table 5Genetic diagnosis results and clinical features of osteogenesis imperfecta, spondyloepiphyseal dysplasia congenita, Stickler syndrome, Jervell Lange-Nielsen syndrome and auditory neuropathy with optic atrophy patients and family members.ProbandFamilyNucleotide changeAmino Acid changeLocationHereditary formSeverity of hering lossOther Clinical FeaturesReferenceRt.earLt.ear**Osteogenesis imperfecta**JHLB459proband*COL1A1*:c.\[903 + 1 G \> A\];\[=\]intron 14ADmoderatemildeasy fracture、blue scleraSchleit (2015)JHLB-3127proband*COL1A1*:c.\[1414 C \> T\];\[=\]p\[R472X\];\[=\]exon 21ADprofoundprofoundeasy fracture、blue scleraPollitt (2006)mother*COL1A1*:c.\[1414 C \> T\];\[=\]p\[R472X\];\[=\]exon 21severeprofoundeasy fracture、blue sclerafather*COL1A1*:c.\[=\];\[=\]p\[=\];\[=\]normalnormal---JHLB325proband*COL1A1*:c.\[2127 + 2 T \> A\];\[=\]intron 31ADnormalmoderateblue sclera, otosclerosis, easy fractureShaheen (2012)**Spondyloepiphyseal dysplasia congenita**JHLB1192proband*COL2A1*:c.\[3198_3206del\];\[=\]p.\[1066_1069del.\];\[=\]exon 46ADprofoundprofoundcleft palate, short stature, short extremitiesthis studyfather*COL2A1*:c.\[3198_3206del\];\[=\]p.\[1066_1069del.\];\[=\]exon 46moderateseverecleft palate, short stature, short extremitiesmother*COL2A1*:c.\[=\];\[=\]p\[=\];\[=\]NANA**Stickler syndrome**JHLB4194proband*COL11A1*:c.\[1737 + 2 T \> C\];\[=\]intron 17ADmildmildcleft palate,myopia (congenital)this studymother*COL11A1*:c.\[1737 + 2 T \> C\];\[=\]intron 17mildmildcleft palate,myopia (congenital,mild)father (U)*COL11A1*:c.\[=\];\[=\]normalnormalJHLB4190proband*COL11A1*:c.\[3117_3152del\];\[=\]p.\[1039_1051del\];\[=\]exon 41spoadic(*de novo*)mildmildcleft palate,myopia (congenital)this studyfather (U)*COL11A1*:c.\[=\];\[=\]normalnormalmother (U)*COL11A1*:c.\[=\];\[=\]normalnormalbrother (U)*COL11A1*:c.\[=\];\[=\]normalnormalJHLB4181proband*COL11A2*:c.\[4392 + 1 G \> A\];\[=\]intron 61ADmildmilduvula bifida,myopia (acquired,mild)Vikkula (1995)daughter*COL11A2*:c.\[4392 + 1 G \> A\];\[=\]intron 61normalnormalcleft palateSon (U)*COL11A2*:c.\[4392 + 1 G \> A\];\[=\]intron 61normalnormalbrother*COL11A2*:c.\[4392 + 1 G \> A\];\[=\]intron 61moderatemildcleft palate mother *COL11A2*:c.\[4392 + 1G \> A\];\[=\]intron 61moderatemoderate**CHARGE syndrome**\#JHLB448proband*CHD7:*c.\[808delG\];\[=\]p.\[A270fs\];\[=\]exon 2spoadicprofoundprofoundcardiac malformation, laryngomalacia, lower cranial nerve disorder, colobomaSanlaville (2006)mother (U)*CHD7:*c.\[=\];\[=\]p\[=\];\[=\]normalnormal**Jervell and Lange**-**Nielsen syndrome**JHLB4860proband*KCNQ1*: c.\[1484_1485del\];\[520 C \> T\]p.\[T495fs\];\[R174C\]exon 11.exon 3ARmoderate(COR)bilateral superior canal dehiscenceNapolitano (2005),Donger (1997)father*KCNQ1*: c.\[520 C \> T\];\[=\]p.\[R174C\];\[=\]exon 3normalnormalmother*KCNQ1*: c.\[1484_1485del\];\[=\]p.\[T495fs\];\[=\]exon 11normalnormal**Auditory neuropathy with optic atrophy**JHLB-2582proband*OPA1*: c.\[892 A \> C\];\[=\]p.\[S298R\];\[=\]exon 9ADmoderatemoderateamblyopia childhood onset. optic nerve atrophythis studyU: Unaffected family member, AD: Autosomal dominant, AR: Autosomal recessive, COR: Conditioned orientation response audiometory.The reference cDNA sequences NM_000088 for *COL1A1*, NM_001844 for *COL2A1*, NM_001854 for *COL11A1*, NM_080680 for *COL11A2*, NM_017780 for *CHD7*, NM_000218 for *KCNQ1*, NM_015560 for *OPA1*.Table 6Genetic diagnosis results and clinical features of Pendred syndrome patients.ProbandNucleotide changeAmino Acid changeSeverity of hearing lossMalformation of inner earGoiterRt.(dB)Lt.(dB)\#752c.\[919-2 A \> G\];\[1652insT\]c.\[919-2 A \> G\];\[1652insT\]101.25103.75EVA+\#1045c.\[2168 A \> G\];\[2168 A \> G\]p\[.H723R\];\[H723R\]9098.75EVA, IP2+\#2010c.\[2168 A \> G\];\[601-1 G \> A\]p\[.H723R\];c.\[601-1 G \> A\]77.596.25EVA+\#2331c.\[2168 A \> G\];\[2168 A \> G\]p\[.H723R\];\[H723R\]92.5102.5EVA+\#2538c.\[2168 A \> G\];\[2168 A \> G\]p\[.H723R\];\[H723R\]102.557.5EVA+\#2798c.\[2168 A \> G\];\[2168 A \> G\]p\[.H723R\];\[H723R\]56.2598.75EVA+\#3074c.\[2168 A \> G\];\[1707 + 5 G \> A\]p.\[H723R\];c.\[1707 + 5 G \> A\]107.5107.5EVA+\#3994c.\[2168 A \> G\];\[601-1 G \> A\]p\[.H723R\];c.\[601-1 G \> A\]NANAEVA+\#4386c.\[2168 A \> G\];\[2168 A \> G\]p\[.H723R\];\[H723R\]83.7592.5EVA+\#4486c.\[1707+5 G \> A\];\[1707 + 5 G \> A\]c.\[1707 + 5 G \> A\];c.\[1707 + 5 G \> A\]72.598.75EVA+\#4490c.\[1229 C \> T\];\[1229 C \> T\]p.\[T410M\];\[T410M\]92.597.5EVA+\#4545c.\[2168 A \> G\];\[1707 + 5 G \> A\]p.\[H723R\];c.\[1707 + 5 G \> A\]9533.75EVA+JHLB40c.\[2168 A \> G\];\[1707 + 5 G \> A\]p.\[H723R\];c.\[1707 + 5 G \> A\]78.7576.25EVA+JHLB401c.\[2168 A \> G\];0.1707 + 5 G \> Ap.\[H723R\];c.\[1707 + 5 G \> A\]115107.5EVA+JHLB427c.\[1229 C \> T\];\[1229 C \> T\]p.\[T410M\];\[T410M\]97.593.75EVA+JHLB507c.\[2168 A \> G\];\[1229 C \> T\]p.\[H723R\];\[T410M\]8062.5EVA+JHLB572c.\[2168 A \> G\];\[1229 C \> T\]p.\[H723R\];\[T410M\]108.25111.25EVA+JHLB575c.\[1579 A \> C\];\[1707 + 5 G \> A\]p.\[T527P\];c.\[1707 + 5 G \> A\]11077.5EVA+JHLB915c.\[2168 A \> G\];\[367 C \> T\]p.\[H723R\];\[P123S\]115115EVA+JHLB1392c.\[2168 A \> G\];\[601-1 G \> A\]p.\[H723R\];c.\[601-1 G \> A\]111.25100EVA+JHLB1790c.\[2168 A \> G\];\[147 C \> G\]p.\[H723R\];\[S49R\]82.593.75EVA+JHLB2150c.\[2168 A \> G\];\[919-2 A \> G\]p.\[H723R\];c.\[919-2 A \> G\]10591.25EVA+JHLB2286c.\[2168 A \> G\];\[919-2 A \> G\]p.\[H723R\];c.\[919-2 A \> G\]108.75112.5EVA+JHLB2485c.\[1579 A \> C\];\[1229 C \> T\]p.\[T527P\];p.\[T410M\]NANAEVA+JHLB2571c.\[2168 A \> G\];\[919-2 A \> G\]p.\[H723R\];c.\[919-2 A \> G\]100115EVA+JHLB2849c.\[2168 A \> G\];\[1001 + 1 G \> A\]p.\[H723R\];c.\[1001 + 1 G \> A\]97.552.5EVA+JHLB2857c.\[2168 A \> G\];\[919-2 A \> G\]p.\[H723R\];c.\[919-2 A \> G\]107.5113.75EVA+JHLB3229c.\[2168 A \> G\];\[1652insT\]p.\[H723R\];c.\[1652insT\]102.558.75EVA+JHLB3735c.\[1343 C \> T\];\[1229 C \> T\]p.\[S448L\];\[T410M\]53.7558.75EVA, IP2+JHLB4048c.\[2168 A \> G\];\[1229 C \> T\]p.\[H723R\];\[T410M\]96.25105EVA, IP2+JHLB4679c.\[2168 A \> G\];\[1648insT\]p.\[H723R\];c.\[1648insT\]78.7567.5EVA+JHLB4876c.\[1174 A \> T\];\[2162 C \> T\]p.\[N392Y\];\[T721M\]105105EVA+The reference cDNA sequence NM_000441 for *SLC26A4*.

The proband with spondyloepiphyseal dysplasia congenita had a novel truncating variant in *COL2A1*. She and her father, who harbored the same variant, had characteristic clinical features (cleft palate, short stature and short extremities). Their hearing level was severe to profound sensorineural hearing loss.

With regard to Stickler syndrome, we identified pathogenic variants in the *COL11A1* (two cases) and *COL11A2* (one case) genes. All identified variants were truncating (two were splice site, one was frameshift), with the two variants in *COL11A1* being novel. One *COL11A1* and one *COL11A2* variant were identified from an autosomal dominant family, and one *COL11A1* variant was identified from a sporadic case (*de novo*). As to the clinical features of the probands and all family members harboring the same causative gene variants (8 patients in total), hearing loss was observed in 75% of cases (3/3 with *COL11A1* variants, 3/5 with *COL11A2* variants), with the severity of hearing loss being mild to moderate. Two children of the proband with a *COL11A2* variant (JHLB4181) carried the same variant but had normal hearing. Seventy-five percent of cases (6/8) had a cleft palate or uvula bifida (3/3 with *COL11A1* variants, 3/5 with *COL11A2* variants), and all three cases with *COL11A1* variants had congenital myopia. One case harboring a *COL11A2* variant, who was the son of the proband, had no symptoms.

A novel *OPA1* variant was identified in one case who suffered auditory neuropathy with optic atrophy. Two other pathogenic amino acid substitutions have been previously identified in the same position. The proband had amblyopia since infancy, and bilateral moderate sensorineural hearing loss. OAE (Otoacoustic emission) presented a normal response, the ABR (Auditory Brainstem Response) threshold was out of scale, and MRI (magnetic resonance imaging) showed bilateral cochlear nerve hypoplasia. The proband's mother had similar symptoms (no DNA sample was available).

With regard to Pendred syndrome, we identified *SLC26A4* variants in 32 probands with autosomal recessive inheritance or sporadic cases. No variants in *KCNJ10* and *FOXI1* were identified in cases with heterozygous *SLC26A4* variants.

Discussion {#Sec6}
==========

In this study, we conducted a comprehensive analysis of Japanese syndromic hearing loss patients to clarify mutation spectrums and clinical features by using NGS analysis with a multiple syndromic targeted resequencing panel. This analysis had a high diagnostic rate (56%) and was suitable for comprehensive analysis. Further, it allowed us to clarify the types and frequency of causative genes in Japanese syndromic hearing loss patients. In addition, it was particularly useful in cases that only partially fulfilled the respective diagnostic criteria. To the best of our knowledge, this is the first study using targeted resequencing panel analysis for multiple syndromic hearing loss patients.

With regard to BO/BOR syndrome, the causative variants were identified in 32% (19/59) of probands (16 typical, 43 atypical). The diagnostic rate was increased to 75% when we restricted the analysis to typical BO/BOR cases (12/16). Krug *et al*. reported the results of genetic analysis for a large number of BO/BOR patients and identified the causative variants in 36% of cases. Similar to this study, the diagnostic rate was increased to 76% when they restricted subjects to typical BO/BOR cases^[@CR28]^. Unzaki *et al*. analyzed 36 Japanese families with clinically diagnosed BO/BOR syndrome and identified causative genes in 72% of them^[@CR29]^. Thus, the diagnostic rate in this study was similar to the rates in these previous reports. *EYA1* variants account for 95% of the causative gene variants identified in this study. Similarly, *EYA1* was commonly identified in BO/BOR cases in previous studies; 85% in Japanese patients^[@CR29]^ and 93% in French patients^[@CR28]^. *SIX1* variants were identified in 5% (1/19) of the genetically diagnosed cases in this study. This percentage was similar to the results of previous reports^[@CR28],[@CR29]^. No causative gene variants were identified in 25% of the typical BO/BOR syndrome cases in this study. There is a possibility that variants in other genes (such as *SALL1*) or genomic rearrangement (inversion or translocation in chromosome 8) may contribute to these cases. In this study, we also identified one copy number loss with a 2.8 Mb deletion of 8q13.2-q13.3 including the *EYA1* gene in one familial case. The frequency of one copy number loss of the *EYA1* gene was 6% (1/18) in this study. In other reports, copy number loss of the *EYA1* gene was also involved in BO/BOR syndrome, with 7% to 10% or more of cases caused by *EYA1* copy number loss^[@CR28],[@CR29]^. The most frequent clinical feature was hearing loss, which was observed in 97% of cases (31/32), followed by preauricular pits in 88% (29/33). In other reports, the most frequent clinical feature was also hearing loss; however, the frequencies of other symptoms varied, with the frequency of renal symptoms higher in some reports^[@CR28]--[@CR30]^. Chen *et al*. reported renal anomalies in 67% of affected individuals^[@CR31]^, with about 6% of them progressing to renal failure^[@CR32]^. Some of them were asymptomatic in the first decade but required dialysis or renal transplantation in adulthood^[@CR33],[@CR34]^. In this study, only one case showed congenital renal anomalies. One plausible reason for this lower rate of renal anomalies was that we enrolled BO/BOR candidate patients, and information regarding renal anormalies was available for only a limited number of patients (renal ultrasonographic information was available for only 7/34 cases). Therefore, more cases may have had renal symptoms. In cases in which BO/BOR syndrome is suspected clinically or genetically, even in the absence of renal dysfunction in early childhood, renal examination may be important.

It is noteworthy that three cases from two unrelated families with *EYA1* variants presented visual symptoms (progressive disturbance of vision, amblyopia and hypermetropia), but visual symptoms are not typically associated with BOR syndrome. *EYA1* is needed for the formation of the anterior portion of the eye^[@CR35]^. Azuma *et al*. reported one case who presented with congenital cataracts with a BOR phenotype (cervical fistula, unilateral multicystic kidney and conductive hearing loss due to ossicular malformations), and others have also reported cases with visual symptoms (dysopia, cataract, micrognathia, and iris coloboma)^[@CR28],[@CR29],[@CR36]--[@CR38]^. The frequency of amblyopia is reported to be 3.0% to 3.2% in the general population^[@CR39],[@CR40]^, but the frequency of visual symptoms in the *EYA1*-related BO/BOR patients in this study was a little higher (9%). There is a possibility that visual symptoms actually represent a rare clinical feature of BO/BOR syndrome.

Waardenburg syndrome was subdivided into four types based on the clinical findings, and each causative gene was identified. We successfully identified the genetic causes in 80% of WS1 probands (4/5), 71% of WS2 probands (10/14), and 100% of WS4 probands (2/2). Hoth *et al*. reported that point mutations in *PAX3* have been identified in more than 90% of affected individuals with WS1 or WS3^[@CR41],[@CR42]^. In this study, we identified one case each with *MITF* and *SOX10* variants from WS1. *MITF* and *SOX10* variants were generally identified from WS2 or WS4 patients. Similarly, *MITF*, *EDNRB*, and *SOX10* variants were identified from WS1 patients in previous reports^[@CR42]--[@CR44]^. The cause of this inconsistency between phenotype and genotype may be 1) a new genotype-phenotype correlation or 2) the wider distance between the inner canthus in the Japanese population. In the Japanese literature, Motomura reported the inter-inner canthal, inter-outer canthal and inter-pupillary distance for each age group among Japanese (published in Japanese)^[@CR45]^. It appears that the W-index calculated from these data may exceed 1.95 in many age groups (Supplementary Fig. [S5](#MOESM1){ref-type="media"}). In future, it may be necessary to consider ethnic differences when evaluating the W-index. Among the WS2 cases, we identified the causative variants in 29% of cases with *MITF*, in 36% with *SOX10*, and in 7% with *EDNRB*. Pingault *et al*. reported that *MITF* mutations were involved in about 15% of cases, 15% with *SOX10,* and *EDNRB* and *SNAI2* are a small percentage among WS2 patients^[@CR46]^. Bocángel *et al*. reported that *MITF* variants and *SOX10* variants were observed in 12% and 20% of South-eastern Brazilian WS2 cases, respectively^[@CR47]^. Sun *et al*. also reported that the rates of causative genes observed in Chinese WS2 cases were 34% for *MITF* and 45% for *SOX10*, respectively^[@CR48]^. Taken together, these results indicate that *SOX10* variants may be more frequently identified in East Asian WS2 cases.

It is worth noting that we also identified one copy number loss of the *SOX10* gene using NGS read depth data and confirmed by aCGH in three cases. Two probands had a large deletion within the chromosome 22q13.1, a proband had the whole *SOX10* gene deletion, and the other proband in a familial case had a partial deletion of *SOX10*. To date, more than 20 cases caused by copy number variation in *PAX3* or *SOX10* have been reported^[@CR42],[@CR47],[@CR49]--[@CR54]^. We identified one *SOX10*-assiociated WS case with developmental delay and one with Asperger syndrome. Both of these cases carried truncation variants; however, no cases were observed with developmental delay among the *SOX10* CNV cases. Thus, the association between genotype and developmental delay phenotype remains unclear.

In addition, we also identified one familial WS case with variations in phenotype among family members. In the *MITF* family (JHLB1623), the father had only unilateral hearing loss and excessive freckles, and her younger brother had only bilateral severe sensorineural hearing loss, but both had the same variant. It is usually difficult to suspect WS from clinical findings and family history; therefore, the comprehensive syndromic hearing loss panel was useful in such cases who only partially fulfilled the diagnostic criteria.

In conclusion, this analysis using NGS with a multiple syndromic targeted resequencing panel was useful for identifying the causative genes in multiple syndromic hearing loss patients in a short time and with a high diagnostic rate.

Subjects and Methods {#Sec7}
====================

Subjects {#Sec8}
--------

In this study we enrolled total 140 probands with possible syndromic hearing loss who carried hearing loss with one or more associated symptoms typical of each syndrome from our hearing loss cohort of 5,137 patients gathered from 67 cooperative research institutes in Japan as described elsewhere^[@CR55]^ (Detailed numbers for each syndrome are listed in Table [2](#Tab2){ref-type="table"}). We also collected data on the hearing level of each proband and their family members. The severity of hearing was classified as mild (20--40 dB), moderate (41--70 dB), severe (71--95 dB), or profound (\>95 dB). With regard to BO/BOR syndrome, we enrolled the patients who fulfilled the criteria (typical and atypical) described previously^[@CR4]^. Regarding auditory neuropathy, the probands with pathogenic variants in *OTOF* and *DFNB59* were excluded from this study.

Written informed consent was obtained from all patients or their guardians. This study was approved by the Shinshu University Ethical Committee as well as the respective Ethical Committees of the other participating institutions listed below. Akita University Ethical Committee, Iwate Medical University Ethical Committee, Tohoku Rosai Hospital Ethical Committee, Fukushima Medical University Ethical Committee, Yamagata University Ethical Committee, Dokkyo Medical University Ethical Committee, TAKASAKI Ear Nose & Throat Clinic Ethical Committee, Niigata University Ethical Committee, Tokyo Medical University Ethical Committee, Jikei University Ethical Committee, Toranomon Hospital Ethical Committee, Kitasato University Ethical Committee, International University of Health and Welfare Mita Hospital Ethical Committee, National Rehabilitation Center for Persons with Disabilities Ethical Committee, Keio University Ethical Committee, Hamamatsu University Ethical Committee, Shiga University Ethical Committee, Shiga Medical Center for Children Ethical Committee, Osaka University Ethical Committee, Kobe City Medical Center General Hospital Ethical Committee, Hyogo College of Medicine Ethical Committee, Kyoto Prefectural University Ethical Committee, Okayama University Ethical Committee, Yamaguchi University Ethical Committee, Ehime University Ethical Committee, Kyushu University Ethical Committee, Kanda ENT Clinic Ethical Committee, Nagasaki University Ethical Committee, Miyazaki University Ethical Committee, Kagoshima University Ethical Committee, Ryukyus University Ethical Committee, Sapporo Medical University Ethical Committee, Tohoku University Ethical Committee, Jichi Medical University Ethical Committee, Gunma University Ethical Committee, Jyuntendo University Ethical Committee, Yokohama City University Ethical Committee, Mejiro University Ethical Committee, Saitama Medical University Ethical Committee, Abe ENT Clinic Ethical Committee, Tokyo Medical Center Institute of Sensory Organs Ethical Committee, Jichi University Saitama Medical Center Ethical Committee, Aichi Children's Health Medical Center Ethical Committee, Chubu Rosai Hospital Ethical Committee, Kyoto University Ethical Committee, Mie University Ethical Committee, Kansai Medical University Ethical Committee, Kobe University Ethical Committee, Osaka Medical Center and Research Institute for Maternal and Children Health Ethical Committee, Wakayama Medical University Ethical Committee, Kouchi University Ethical Committee, Hiroshima University Ethical Committee, Hiroshima City Hiroshima Citizen Hospital Ethical Committee, Fukuoka University Ethical Committee, Kurume University Ethical Committee, National Defense Medical College Ethical Committee, Tokai University Ethical Committee, Hokkaido University Ethical Committee, Kanagawa Children's Medical Center Ethical Committee, Tokyo Medical and Dental University Ethical Committee, Hirosaki University Ethical Committee, Tokyo Metropolitan Children's Medical Center Ethical Committee, Hakodate Central General Hospital Ethical Committee, Osaka Red Cross Hospital Ethical Committee, Hiroshima Prefectural Hospital Ethical Committee, Nara Medical University Ethical Committee, Tsukuba University Ethical Committee. All methods were performed in accordance with the Guidelines for Genetic Tests and Diagnoses in Medical Practice of the Japanese Association of Medical Sciences and the Declaration of Helsinki as required by Shinshu University.

Methods {#Sec9}
=======

Amplicon Library Preparation {#Sec10}
----------------------------

An Amplicon library was prepared with an Ion AmpliSeq^TM^ Custom Panel (Applied Biosystems, Life Technologies) for 36 target genes reported to cause syndromic hearing loss. We selected the 36 genes associated with 14 types of syndromic hearing loss commonly observed in practical settings. We also referred to the hereditary hearing loss homepage (<https://hereditaryhearingloss.org>) to select these genes. The responsible genes for Usher syndrome were not included in our syndromic hearing loss targeting panel as these genes were included in the non-syndromic hearing loss panel reported in a previous paper^[@CR55]^. To avoid any overlap between these two panels, we removed the genes associated with Usher syndrome from our panel. The panel contained the following genes: *EYA1*-*SIX1*-*SIX5 for* BOR syndrome; *PAX3*-*MITF*-*SNAI2*-*EDNRB*-*EDN3*-*SOX10* for Waardenburg syndrome; *COL2A1*-*COL11A1*-*COL11A2*-*COL9A1*-*COL9A2*-*COL9A3*-*COL1A1*-*COL4A3*-*COL4A4*-*COL4A5* for connective tissue disorder including osteogenesis imperfecta, spondyloepiphyseal dysplasia congenita, Stickler syndrome, and Alport syndrome; *CHD7*-*SEMA3E* for CHRGE syndrome; *SLC26A4*- *FOXI1*-*KCNJ10* for Pendred syndrome; *KCNQ1*-*KCNE1* for Jervell Lange-Nielsen syndrome; *NDP* for Norrie disease; *TCOF1*-*POLR1C* for Treacher-Collins syndrome, *HSD17B4*-*HARS2*-*CLPP*-*LARS2* for Perrault syndrome; *OPA1* for auditory neuropathy with optic atrophy and *GDF6*-*MEOX1* for Klippel Feil syndrome.

Emulsion PCR and sequencing {#Sec11}
---------------------------

The emulsion PCR and NGS (next-generation sequencing) were performed with an Ion Proton system using the Ion Proton 200 sequencing Kit and an Ion P1 Chip (ThermoFisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions.

Base call and data analysis {#Sec12}
---------------------------

The sequence data were mapped against the human genome sequence (build GRCh37/hg19) with the Torrent Mapping Alignment Program. After sequencing mapping, the DNA variant regions were piled up with Torrent Variant Caller plug-in software. After variant detection, variant effects were analyzed using the ANNOVAR software^[@CR56],[@CR57]^.

Direct sequencing {#Sec13}
-----------------

After the filtering process, described previously^[@CR55]^, we performed confirmation of the identified variant and family segregation analysis by Sanger sequencing.

CNV (Copy Number Variation) analysis {#Sec14}
------------------------------------

CNV analysis was performed with NGS analysis read depth data according to the method described in a previous report^[@CR58]^.

aCGH (Array Comparative Genomic Hybridization) {#Sec15}
----------------------------------------------

To confirm the CNVs identified from NGS read depth data, we performed array CGH analysis with the Agilent 8 × 60 K whole genome array (Agilent Technologies, Santa Clara, CA). We used the same DNA samples as for the amplicon re-sequencing, and quality assessment was also carried out. Ten microliters of genomic DNA solution (0.5ug of DNA) were fragmented, labeled with cyanine-3 for reference DNA samples and cyanine-5 for subjects, and then hybridized. Scanning of the array was carried out according to the manufacturer's recommended protocols. Scanned aCGH data were analyzed using CytoGenomics software version 3.0.6.6 (Agilent Technologies).
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